Travere’s FSGS Launch Roars Out of the Gate, Cementing a New Growth Era
Travere Therapeutics has entered what CEO Eric Dube calls “a new chapter” – and the second-quarter 2026 results confirm the transformation is real. The company delivered record U.S. net product sales of $161.4 million, with FILSPARI alone growing ~96% year-over-year to $141.1 million. Underpinning this is the first full quarter of FILSPARI availability in both IgA nephropathy (IgAN) and the newly approved FSGS indication. With over 2,000 new patient start forms (PSFs) across both indications, the commercial engine is firing on all cylinders.
The launch momentum in FSGS is the headline. FSGS launch dynamics have exceeded management’s high expectations, as Peter Heerma noted: “All fundamentals regarding demand, payer access, fulfillment and revenue are exceeding the metrics we have seen during the initial phase of the IgA nephropathy launch.” What is striking is that the shape of the curve differs from IgAN – “In FSGS, those foundational elements were already in place at launch, enabling broader adoption earlier in the launch curve.” Indeed, the FSGS uptake is broad, with the vast majority of prescribers having written for a single patient so far, implying significant depth remains to be unlocked. The earlier launch took distinct phases tied to regulatory milestones; this one is front-loaded, a point management stressed repeatedly.
Their efforts resulted in record FILSPARI demand with over 2,000 new patient start forms across IgA nephropathy and FSGS and record U.S. revenue of more than $141 million for the quarter.
The company is also strategically widening its portfolio beyond FILSPARI. Pegtibatinase, a potential first-in-class therapy for classical homocystinuria (HCU), is progressing in a Phase III study with data expected in 2H 2027. More notably, Travere closed an exclusive licensing agreement with Everest Medicines for rare kidney disease-focused novel BTK inhibitor civorebrutinib, adding an immune-modulating mechanism complementary to FILSPARI’s kidney-protective effects. Jula Inrig said the company is “excited to officially bring civorebrutinib into our development portfolio,” with potential in primary membranous nephropathy and other immune-mediated kidney diseases. The pipeline is no longer a one-trick pony.
Financially, the company is in its strongest position in years. Cash, cash equivalents, and marketable securities stood at ~$489 million at the end of June, before the $112.5 million civorebrutinib payment in July. Management also completed a convertible refinancing – repurchasing ~$221 million of 2029 notes and issuing $525 million of 0.5% notes due 2032 – lowering interest costs and extending maturities. The balance sheet is now positioned to fund a multi-asset strategy without equity dilution. From a fundamentals perspective, revenue growth has been explosive, though the company is still investing heavily in R&D (up 22% YoY) and SG&A for the launch.
This quarter’s performance was not entirely unpredictable. On the prior call, Peter Heerma had already flagged confidence in a faster FSGS ramp: “we are confident in a faster uptake in FSGS relative to the IgA nephropathy launch for multiple reasons.” — Peter Heerma, President, U.S. Commercial Operations or similar · 2026-05-04 And even earlier, the company had set the stage with robust IgAN demand – “we are very happy with the very strong demand exceeding 900.” — Peter Heerma, Unknown · 2026-02-19 But the magnitude of the beat – with record PSFs and revenue – immediately validates the bull case.
Competition is emerging, notably from Otsuka’s APRIL inhibitor and Novartis’ atrasentan, but Travere is positioning FILSPARI as the foundational nephroprotective agent, not a me-too. Management reiterated confidence in the $3 billion peak-sales opportunity across both indications, citing that penetration remains early. The launch is still only scratching the surface of an estimated 30,000 addressable FSGS patients – and with a broad prescriber base that is just starting to repeat, the runway is long.
Investor response has been euphoric: the stock has risen more than 125% in the last 90 days, a reflection of the de-risking of the FSGS opportunity. The convertible note transactions and patent progress further bolster the thesis. The question now is execution drift – management will need to convert early enthusiasm into sustained quarterly growth. But with a strong balance sheet, multiple catalysts ahead, and a clear strategic focus, Travere appears well-poised to deliver on its rare-disease ambitions.